<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867214</url>
  </required_header>
  <id_info>
    <org_study_id>XJODCT2014003</org_study_id>
    <nct_id>NCT03867214</nct_id>
  </id_info>
  <brief_title>The Efficacy of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty</brief_title>
  <official_title>The Efficacy of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanzhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, single-center and controlled study comparing the efficacy and
      safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous
      bilateral total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, single-center and controlled study comparing the efficacy and
      safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous
      bilateral total knee arthroplasty. Subjects will be monitored for occurrence of any
      complications, particularly deep venous thrombosis and thromboembolism during the hospital
      stay and for 1 months postoperatively
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Allogeneic Blood Transfusion as a Measure of Efficacy</measure>
    <time_frame>one week after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving TXA, Study group
Tranexamic acid, Study group tranexamic acid 1g,
intravenous injection, pre-operationally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, Control group
Not receiving tranexamic acid, Control group Normal
saline 100mL, intravenous injection, pre-operationally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>100 mL of normal saline intravenously approximately 15 minutes before incision</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients who plan to undergo simultaneous primary total knee arthroplasty on
             bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but
             not of rheumatoid arthritis;

          -  All patients who have normal preoperative platelet count, normal prothrombin time,
             normal partial thromboplastin time, and normal international normalized ratio;

          -  The use of only balanced electrolyte solutions and/or albumin for plasma volume
             restitution.

        Exclusion Criteria:

          -  Allergy to tranexamic acid;

          -  Receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis,
             pulmonary embolism, or renal impairment; or were pregnant;

          -  Patients with any cardiovascular problems (such as myocardiac infarction history,
             atrial fibrillation, angina);

          -  Patients with thromboembolic disorders, or those exhibiting a deteriorating general
             condition;

          -  Preoperative anemia (a hemoglobin value of &lt;11 g/dL in females and &lt;12 g/dL in males),
             refusal of blood products;

          -  Preoperative use of anticoagulant therapy within five days before surgery,
             fibrinolytic disorders requiring intraoperative antifibrinolytic treatment,
             coagulopathy (as identified by a preoperative platelet count of &lt;150,000/mm3, an
             international normalized ratio of &gt;1.4, or a prolonged partial thromboplastin time
             [&gt;1.4 times normal]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingsheng Zhu</last_name>
    <role>Study Director</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Yan, MD</last_name>
    <phone>+86-29-84775280</phone>
    <email>yanzhaoii@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chongfei Yang, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Yanzhao</investigator_full_name>
    <investigator_title>Orthopaedic Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

